150 related articles for article (PubMed ID: 38594056)
21. Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry.
Pappas DA; O'Brien J; Guo L; Shan Y; Baker JF; Kricorian G; Stryker S; Collier DH
Arthritis Res Ther; 2023 Sep; 25(1):166. PubMed ID: 37689684
[TBL] [Abstract][Full Text] [Related]
22. Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry.
Mok CC; So H; Yim CW; To CH; Lao WN; Wong SPY; Ng HY; Lee JMY; Lee PML; Ying SKY; Leung MH; Ho CTK
Rheumatology (Oxford); 2024 Feb; 63(2):358-365. PubMed ID: 37129549
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
Finckh A; Tellenbach C; Herzog L; Scherer A; Moeller B; Ciurea A; von Muehlenen I; Gabay C; Kyburz D; Brulhart L; Müller R; Hasler P; Zufferey P;
RMD Open; 2020 May; 6(1):. PubMed ID: 32385143
[TBL] [Abstract][Full Text] [Related]
24. Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register.
Meissner Y; Schäfer M; Albrecht K; Kekow J; Zinke S; Tony HP; Strangfeld A
RMD Open; 2023 Oct; 9(4):. PubMed ID: 37880180
[TBL] [Abstract][Full Text] [Related]
25. Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis.
Venetsanopoulou AI; Voulgari PV; Drosos AA
Expert Rev Clin Immunol; 2022 May; 18(5):485-493. PubMed ID: 35535405
[TBL] [Abstract][Full Text] [Related]
26. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis.
Molander V; Bower H; Frisell T; Delcoigne B; Di Giuseppe D; Askling J;
Ann Rheum Dis; 2023 Feb; 82(2):189-197. PubMed ID: 36150749
[TBL] [Abstract][Full Text] [Related]
27. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.
Amstad A; Papagiannoulis E; Scherer A; Rubbert-Roth A; Finckh A; Mueller R; Dudler J; Möller B; Villiger PM; Schulz MMP; Kyburz D
Rheumatology (Oxford); 2022 Dec; 62(1):89-97. PubMed ID: 35579338
[TBL] [Abstract][Full Text] [Related]
28. Real-world utilisation and switching between Janus kinase inhibitors in Australian patients with rheumatoid arthritis in the OPAL dataset.
Ciciriello S; Littlejohn GO; Treuer T; Gibson KA; Haladyj E; Youssef P; Bird P; O'Sullivan C; Smith T; Deakin CT
Clin Exp Rheumatol; 2024 May; ():. PubMed ID: 38757292
[TBL] [Abstract][Full Text] [Related]
29. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research.
Kerschbaumer A; Smolen JS; Nash P; Doerner T; Dougados M; Fleischmann R; Geissler K; McInnes IB; Takeuchi T; Trauner M; Winthrop K; de Wit M; Boehncke WH; Falzon L; van der Heijde D
RMD Open; 2020 Nov; 6(3):. PubMed ID: 33188136
[TBL] [Abstract][Full Text] [Related]
30. Treatment Patterns of Biologic Disease-Modifying Antirheumatic Drugs and Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis in Japan: A Claims-Based Cohort Study.
Miyashiro M; Asano T; Ishii Y; Miyazaki C; Shimizu H; Masuda J
Drugs Real World Outcomes; 2024 Jun; 11(2):285-297. PubMed ID: 38598110
[TBL] [Abstract][Full Text] [Related]
31. Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry.
Pombo-Suarez M; Sanchez-Piedra C; Garcia-Magallón B; Pérez-Gómez A; Manrique-Arija S; Martín-Doménech R; Colazo M; Campos C; Campos J; Del Pino-Montes J; Arteaga MJ; Cea-Calvo L; Díaz-González F; Gómez-Reino JJ
Clin Rheumatol; 2021 Oct; 40(10):3979-3988. PubMed ID: 33907904
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease-modifying antirheumatic drugs: A multi-centre cohort study.
Tong X; Shen CY; Jeon HL; Li Y; Shin JY; Chan SC; Yiu KH; Pratt NL; Ward M; Lau CS; Wong IC; Li X; Lai EC
J Intern Med; 2023 Sep; 294(3):314-325. PubMed ID: 37282790
[TBL] [Abstract][Full Text] [Related]
33. Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases.
Pombo-Suárez M; Seoane-Mato D; Díaz-González F; Sánchez-Alonso F; Sánchez-Jareño M; Cea-Calvo L; Castrejón I
Adv Rheumatol; 2023 Jun; 63(1):25. PubMed ID: 37287051
[TBL] [Abstract][Full Text] [Related]
34. Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis: A Decision Tree Analysis by Indication.
Dalén J; Svedbom A; Hernlund E; Olofsson T; Black CM
Adv Ther; 2023 Oct; 40(10):4657-4674. PubMed ID: 37599341
[TBL] [Abstract][Full Text] [Related]
35. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
Flouri ID; Markatseli TE; Boki KA; Papadopoulos I; Skopouli FN; Voulgari PV; Settas L; Zisopoulos D; Iliopoulos A; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
J Rheumatol; 2018 Jun; 45(6):785-794. PubMed ID: 29606666
[TBL] [Abstract][Full Text] [Related]
36. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies.
Gialouri CG; Moustafa S; Thomas K; Hadziyannis E; Vassilopoulos D
Rheumatol Int; 2023 Mar; 43(3):421-435. PubMed ID: 36635577
[TBL] [Abstract][Full Text] [Related]
37. Drug efficacy and safety of biologics and Janus kinase inhibitors in elderly patients with rheumatoid arthritis.
Ebina K
Mod Rheumatol; 2022 Feb; 32(2):256-262. PubMed ID: 34894239
[TBL] [Abstract][Full Text] [Related]
38. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
Sparks JA; Wallace ZS; Seet AM; Gianfrancesco MA; Izadi Z; Hyrich KL; Strangfeld A; Gossec L; Carmona L; Mateus EF; Lawson-Tovey S; Trupin L; Rush S; Katz P; Schmajuk G; Jacobsohn L; Wise L; Gilbert EL; Duarte-García A; Valenzuela-Almada MO; Pons-Estel GJ; Isnardi CA; Berbotto GA; Hsu TY; D'Silva KM; Patel NJ; Kearsley-Fleet L; Schäfer M; Ribeiro SLE; Al Emadi S; Tidblad L; Scirè CA; Raffeiner B; Thomas T; Flipo RM; Avouac J; Seror R; Bernardes M; Cunha MM; Hasseli R; Schulze-Koops H; Müller-Ladner U; Specker C; Souza VA; Mota LMHD; Gomides APM; Dieudé P; Nikiphorou E; Kronzer VL; Singh N; Ugarte-Gil MF; Wallace B; Akpabio A; Thomas R; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Robinson PC; Machado PM; Yazdany J;
Ann Rheum Dis; 2021 Sep; 80(9):1137-1146. PubMed ID: 34049860
[TBL] [Abstract][Full Text] [Related]
39. Real-world effectiveness of biological therapy in patients with rheumatoid arthritis: Systematic review and meta-analysis.
de Castro CT; de Queiroz MJ; Albuquerque FC; Brandão CC; Gerlack LF; Pereira DCR; Barros SC; Andrade WW; Bastos EA; Azevedo JNB; Carreiro R; Barreto ML; Dos Santos DB
Front Pharmacol; 2022; 13():927179. PubMed ID: 36034836
[No Abstract] [Full Text] [Related]
40. Changes in the cholesterol profile of patients with rheumatoid arthritis treated with biologics or Janus kinase inhibitors.
Koh JH; Lee BW; Kim WU
J Rheum Dis; 2023 Oct; 30(4):234-242. PubMed ID: 37736594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
